

Natasa Djordjevic CV

June, 2015

Personal Data

Full name **Natasa D. Djordjevic**
Birth date August 6, 1975
Birth place Cuprija, Serbia
E-mail natashadj2002@yahoo.com
natasa.djordjevic@medf.kg.ac.rs
Natasa.Djordjevic@ucsf.edu
Phone +381 69 877 66 75
Address: Department of Pharmacology and Toxicology
Faculty of Medical Sciences, University of Kragujevac
Svetozara Markovica 69, 34 000 Kragujevac, Serbia

Education and Academic Degrees

Board Certification 2013, Clinical Pharmacology, Faculty of Medical Sciences, University of Kragujevac, Serbia
Doctor of Philosophy degree (PhD) 2012, Clinical Pharmacology - Pharmacogenetics, Karolinska Institute, Stockholm, Sweden
2008, Clinical and Experimental Pharmacology, Medical Faculty, University of Kragujevac, Serbia
MD diploma validation 2004, Medical Faculty, University of Ljubljana, Slovenia
Master of Science degree (MSc) 2003, Clinical and Experimental Pharmacology, Medical Faculty, University of Kragujevac, Serbia
Medical Doctor degree (MD) 2000, Medical Faculty, University of Kragujevac, Serbia; licence No: 401528

Professional Positions

2015 Visiting Associate Professor, Department of Pathology, University of California San Francisco, San Francisco, USA
2013 - present Associate Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2008 - 2013 Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2012 - 2013 Assistant Professor, US Medical School, Belgrade, Serbia
2004 - 2008 Teaching Assistant, Department of Pharmacology and Toxicology, Medical Faculty, University of Kragujevac, Kragujevac, Serbia
2002 -2004 General practitioner, Health Center "Miloje Hadzic-Sule", Raca, Serbia

Scholarships

2015 Fulbright Visiting Scholar Program, United States Department of State, Bureau of Educational and Cultural Affairs
2006 - 2007 Guest Scholarship Programme, Swedish Institute

Languages

Serbian	Native
English	Excellent
Slovenian	Elementary

Publications

PhD theses

Djordjevic N. Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO [dissertation]. Stockholm: Karolinska Institute; 2012.

Djordjevic N. [Pharmacogenetics of drug metabolizing enzymes CYP1A2 and CYP2A6 in Serbian population] [dissertation]. Kragujevac: Medical Faculty University of Kragujevac; 2008. Serbian.

Master's thesis Djordjevic N. [Characteristics of decision making process during prescribing] [master's thesis]. Kragujevac: Medical Faculty University of Kragujevac; 2003. Serbian.

Papers *In extenso*

- 1 Dragas Milovanovic D, Radosavljevic I, Radovanovic M, Milovanovic J, Obradovic S, Jankovic S, Milovanovic D, Djordjevic N. CYP3A5 polymorphism in Serbian pediatric epileptic patients on carbamazepine treatment. Ser J Exp Clin Res. Forthcoming 2015.
- 2 Radosavljevic I, Milojevic A, Miljkovic J, Divjak A, Jelic I, Artinovic V, Spasic M, Stojanovic B, Canovic P, Jankovic, S, and Djordjevic, N. Lack of PRSS1 and SPINK1 polymorphism in Serbian acute pancreatitis patients. Ser J Exp Clin Res. Forthcoming 2015.
- 3 Dagovic A, Matter Walstra K, Gutzwiller SF, Djordjevic N, Rankovic A, Djordjevic G, Kocic S, Vasiljevic D, Canovic P, Kovacevic A, Aleksandar D, Dragojevic Simic V, Jakovljevic M, Schwenkglens M. Resource use and costs of newly diagnosed cancer initial medical care. Eur J Oncol 2014; 19 (3): 166-84.
- 4 Jakovljevic M, Djordjevic N, Jurisevic M, Jankovic S. Evolution of Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):521-30.
- 5 Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT software induced savings on medical costs of alcohol addicts' care - Results from a matched-pairs case-control study. PLoS One. 2014;9(11):e111931.
- 6 Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS. 2014;18(7):446-53.
- 7 Obradovic J, Jurisic V, Tosic N, Mrdjanovic J, Perin B, Pavlovic S, and Djordjevic N. Optimization of PCR conditions for amplification of GC-rich EGFR promoter sequence. JCLA 2013; 27 (6): 487–93.
- 8 Jakovljevic MB, Mijailovic ZD, Popovska Jovicic BD, Canovic PS, Gajovic OM, Jovanovic MR, Petrovic DS, Milovanovic OZ, and Djordjevic ND. Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-interferon-2α + ribavirine treated chronic hepatitis C patients. Hepatitis Monthly 2013; 13(6): e6750.
- 9 Jakovljevic M, Riegler A, Jovanovic M, Djordjevic N, Patek K, Lesch O, Walter H. Serbian and Austrian alcohol-dependent patients: a comparison of two samples regarding therapeutically relevant clinical features. Alcohol Alcohol. 2013; 48(4): 505-8.
- 10 Djordjevic N, Jankovic S, Stepanovic M, Milovanovic D. [A report of a medication error – drug incompatibility]. Med Cas (Krag) 2013; 47(1): 39-41. Serbian.
- 11 Djordjevic N, Carrillo JA, van den Broek MPJ, Kishikawa J, Roh HK, Bertilsson L, Aklillu E.

- Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. *Drug Metab Pharmacokinet* 2013; 28(2): 93-7.
- 12 Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E. Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. *J Clin Pharmacol* 2012; 52(10):1527-34.
 - 13 Radosavljevic I, Djordjevic N. [Influence of genetic polymorphism on the course and outcome of acute pancreatitis]. *Rational Therapy* 2011; 3(2): 17-21. Serbian.
 - 14 Djordjevic N. [Vitamins and trace elements in sport]. *Rational Therapy* 2011; 3(1): 23-7. Serbian.
 - 15 Djordjevic N, Bogojevic J, Kostic M. Alcohol consumption among adolescents in Kraljevo, Serbia. *Cent Eur J Med* 2011; 6(3): 363-71.
 - 16 Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, Jankovic S, Aklillu E. N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a white population. *J Clin Pharmacol* 2010; 51: 7: 994-1003.
 - 17 Andjelic S, Djordjevic N. Out-of-hospital cardiopulmonary resuscitation in four Serbian university cities: outcome follow-up according to the "Utstein style". *Signa Vitae* 2010; 5(1): 27-33.
 - 18 Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. *Eur J Clin Pharmacol* 2010; 66(7):697-703.
 - 19 Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. *Eur J Clin Pharmacol* 2010; 66(6): 571-20
 - 20 Djordjevic N, Jankovic S. [Prescribing in general practice]. *Med Cas (Krag)* 2008; 2: 26-30. Serbian.
 - 21 Djordjevic N, Ghotbi R, Jankovic S, Bertilsson L, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. *Eur J Clin Pharmacol* 2008; 64(4): 381-5.
 - 22 Djordjevic N, Jankovic S. [Pharmacogenetics – future of the drug therapy]. *Acta Medica Medianae* 2007;46(2): 57-62. Serbian.
 - 23 Djordjevic N, Metiljevic Z, Jankovic S, Milovanovic D, Ilic M, Ruzic-Zececic D. [Cancer education within Medical Faculty curricula: comparison between Kragujevac and Zagreb]. *Medicus* 2007; 7(3): 126. Serbian.
 - 24 Djordjevic ND, Jankovic SM. [Characteristics of decision-making process during prescribing in general practice]. *Vojnosanit Pregl* 2006; 63(3): 279-85. Serbian.
 - 25 Djordjevic N, Jankovic S. [Actions for the improvement of medical practice]. *Vojnosanit Pregl* 2004; 61(4): 423-31. Serbian.

Selected Book Chapters

- 1 Djordjevic N. [Cost minimisation studies]. In: Jakovljevic M, editor. *Health economics with pharmacoeconomy*. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2014. p. 413-5. Serbian.
- 2 Djordjevic N. [Cost-effectiveness of diagnostic tests studies]. In: Jakovljevic M, editor. *Health economics with pharmacoeconomy*. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2014. p. 440-3. Serbian.
- 3 Djordjevic N. [Drug interactions. Synergism and antagonism]. In: Djordjevic N, ed. [Laboratory practicals in pharmacology]. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2013. p. 18-20. Serbian.
- 4 Djordjevic N. [The influence of cholinergic neurotransmission on the cardiovascular system]. In: Djordjevic N, ed. [Laboratory practicals in pharmacology]. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2013. p. 21-5. Serbian.
- 5 Djordjevic N. [The influence of adrenergic agonists on the cardiovascular system]. In: Djordjevic N,

ed. [Laboratory practicals in pharmacology]. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2013. p. 26-32. Serbian.

- 6 Djordjevic N. [Nonsteroidal anti-inflammatory drugs]. In: Jankovic S, ed. [Pharmacology and Toxicology]. Kragujevac: Medical Faculty University of Kragujevac; 2011. p. 299-311. Serbian.
- 7 Djordjevic N. [Acetaminophen]. In: Jankovic S, ed. [Pharmacology and Toxicology]. Kragujevac: Medical Faculty University of Kragujevac; 2011. p. 312-5. Serbian.
- 8 Djordjevic N. [Anti-TNF Reagents]. In: Jankovic S, ed. [Pharmacology and Toxicology]. Kragujevac: Medical Faculty University of Kragujevac; 2011. p. 316-9. Serbian.

Book Editing

- 1 Djordjevic N, ed. [Laboratory practicals in pharmacology]. Kragujevac: Faculty of Medical Sciences University of Kragujevac; 2013. p. 77.

Selected Abstracts and Presentations

- 1 Djordjevic N, Dragas Milovanovic D, Radovanovic M, Radosavljevic I, Obradovic S, Milovanovic J, Milovanovic D. *CYP2C8*3* polymorphism and steady-state carbamazepine plasma concentrations in epileptic patients: preliminary results. *Eur Neuropsychopharmacol.* 2014;24(Suppl 2): S157. (poster presentation)
- 2 Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT software attributed net savings on costs of alcohol addicts hospital care. The 22nd European Psychiatric Association (EPA) Congress, Article – EPA - 1505, 01-04 March 2014 Munich, Germany (poster presentation)
- 3 Jakovljevic M, Riegler A, Jovanovic M, Djordjevic N, Patek K, Lesch OM, Walter H. LAT software based comparative clinical trial of alcohol addicts in Serbia and Austria. *Journal of the Neurological Sciences* 2013; 333: e586. (poster presentation)
- 4 Aklillu E, Djordjevic N. In vivo evaluation of P-glycoprotein as a potential transporter for caffeine. Poster presented at: Proceedings of the Keystone Symposium Human Genomics and Personalized Medicine; 2013 June 17-21; Stockholm, Sweden. (poster presentation)
- 5 Djordjevic N, van den Broek MPJ, Carrillo JA, Roh HK, Bertilsson L, Aklillu E. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. *ISSX Online Abstracts* 2012; 1 (Suppl 7). (poster presentation)
- 6 Djordjevic N, Carrillo JA, Gervasini G, Ueda N, Roh H, Aklillu E. Xanthine oxidase and N-acetyltransferase-2 enzyme activities in Swedes and Koreans: an inter-ethnic comparison. *Basic Clin Pharmacol Toxicol* 2011; 109 (Suppl.1): 23-4. (oral presentation)
- 7 Djordjevic N. [Practical implementation of of pharmacogenetics]. *Rational Therapy* 2011; 3(1): 51-2. Serbian. (oral presentation)
- 8 Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Poster presented at: ESF-UB Conference in Biomedicine Pharmacogenetics and Pharmacogenomics: Practical Applications in Routine Medical Practice; 2010 June 6-11; Sant Feliu de Guixols, Spain. (poster presentation)
- 9 Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. [Investigation of *in vivo* XO enzyme activity in Serbian population]. *Med Cas (Krag)* 2009; 43(1) Suppl 1: 21. Serbian. (poster presentation)
- 10 Djordjevic N, Bogojevic J, Kostic M. [Characteristics of alcohol consumption among adolescents in our surroundings]. *Med Cas (Krag)* 2009; 43(1) Suppl 1: 27. Serbian. (poster presentation)
- 11 Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. Correlation of CYP2A6 enzyme activity with genotype and cigarette smoking in Serbs. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl.1): 21-

2. (oral presentation)
- 12 Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: Unprecedented high prevalence of rapid acetylators in a white population. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl.1): 81. (poster presentation)
 - 13 Djordjevic N, Jankovic S, Bertilsson L, Aklillu E. [*CYP3A4* and *CYP3A5* genetic polymorphism in Serbs]. *Med Cas (Krag)* 2008; 42(1) Suppl 1: 29. Serbian. (poster presentation)
 - 14 Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E. Genetic polymorphism and enzyme activity of CYP1A2 in Serbs: induction by cigarette smoking and heavy coffee consumption. *Pharmaca Iugoslavica* 2008; 43(1-2): 49-50.
 - 13 Djordjevic ND, Jankovic SM. Characteristics of decision making process during prescribing. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 2004; 18: 99. (poster presentation)

Conference reports

- 1 Djordjevic N. [Conference report. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, 26-29.06.2011, Budapest]. *PONS Med J* 2011; 8(3): 106. Serbian.
- 2 Djordjevic N. Conference report. Swedish pharmacogenetic network meeting 2007. *Medicus* 2007; 8(2): 76.

Bibliometrics

Scopus (ID: 15724847000) Citations: 59; h index: 3
 Google scholar Citations: 160; h index: 6; i10-index: 3

Scientific projects

International

- 2015 - present University of California, San Francisco, USA; title: "Diagnostic and prognostic relevance of LC3, p62, Nrf2 and Keap1 genetic profile in sporadic inclusion body myositis" (investigator)
- 2012 - present Medical Faculty University of Montenegro; title: "Analysis of risk factors for adverse drug reactions in cardiology patients" (investigator)

National

- 2011 - present Ministry of Education and Science, Serbia; Project No 175007, title: "Pharmacology analysis of effect of biologically active substances on smooth muscle in gastrointestinal and urogenital tract in human" (investigator)
- 2011 - present Ministry of Education and Science, Serbia; Project No 175056, title: "Molecular, biochemical and immunology diagnostics of cancer" (investigator)
- 2011- 2014 Faculty of Medical Sciences University of Kragujevac, Serbia; JP 10/11, title: "The influence of genetic polymorphism of pancreas proteins and mediators of inflammation on the course and outcome of acute pancreatitis" (principal investigator)
- 2011- 2014 Faculty of Medical Sciences University of Kragujevac, Serbia; JP 07/11, title: "The influence of genetic polymorphism on efficacy and safety of carbamazepine therapy in children" (principal investigator)
- 2009 - present Faculty of Medical Sciences University of Kragujevac, Serbia; JP 07/09, title: "Influence of genetic polymorphism of drug metabolising enzymes and their inducers on clinical response to olanzapine therapy" (investigator)
- 2005 - 2008 Medical Faculty University of Kragujevac, Serbia; JP 01/05, title: "Genotypisation of four

variant alleles of CYP1A2 gene in Serbian population" (principal investigator)

Professional Organization Memberships and Service

Member	Serbian Medical Chamber, 2007 - present Serbian Medical Society, 2010 - present
Non-clinical Expert	Agency for Medicines and Medical Devices of Serbia, 2013 - present Agency for Medicines and Medical Devices of Montenegro, 2012 - present
Journal Review	The Journal of Clinical Pharmacology; Frontiers in Pharmacogenetics and Pharmacogenomics; The American Journal of Clinical Nutrition; International Journal of Pharmacy and Pharmacology; African Journal of Pharmacy and Pharmacology; Central European Journal of Medicine; Educational Research; Universal Journal of Education and General Studies; Medical Journal [Serbian]; Rational Therapy [Serbian]; Timok Medical Journal [Serbian]; PONS [Serbian]
Book review	Jankovic S, ed. [Good practice within ethics committees]. Kragujevac: Medical Faculty University of Kragujevac; 2009. 129p. Serbian.

Selected CME

2015	UCSF, San Francisco, USA (visiting scientist)
2014	4th National Congress of Rational Therapy in Medicine, MEDRAT, Kragujevac, Serbia (participant and oral presenter)
2013	Keystone Symposia Conference: Human Genomics and Personalized Medicine, Stockholm, Sweden (participant)
2013	Professional meeting of the Serbian Pharmacology Society, Kragujevac, Serbia (participant and oral presenter)
2012	19th Microsomes and Drug Oxidations (MDO) and 12th European International Society for the Study of Xenobiotics (ISSX) meeting, Noordwijk aan Zee, the Netherlands (participant)
2011	Karolinska Institute, Stockholm, Sweden (visiting scientist)
2011	Basic Course in Medical Statistics, Karolinska Institute, Stockholm, Sweden (participant)
2011 - 2012	NIH Clinical Center course "Principles of clinical pharmacology", The National Institutes of Health, Bethesda, Maryland (participant)
2011	Professional Meeting of the Society of Pharmacists of Nisavsko-Pirotski Region "Pharmacogenetics in science and practice", Nis, Serbia (invited speaker)
2011	Karolinska Institute, Stockholm, Sweden (study visit)
2010	Continuing Medical Education "Research methodology in medicine and pharmacy", Faculty of Medical Science, Kragujevac, Serbia (participant)
2010	Continuing Medical Education "Good clinical practice - the role, objectives and principles of the Ethical Committee of healthcare institutions", Faculty of Medical Science, Kragujevac, Serbia (participant)
2009	Symposium of the Serbian Medical Society, Section of Clinical Pharmacology "The week of hospital clinical pharmacology", Belgrade, Serbia (invited speaker)
2009	7th European Summer School in Clinical Pharmacology & Therapeutics, Alexandroupolis, Greece (participant)
2009	Pharmacovigilance: regulatory and practical aspects, Belgrade/Kragujevac, Serbia (participant)
2008	Pharmacogenomics/-genetics course, DIRAC, IUPHAR & EACPT, Helsingør, Denmark

	(participant)
2006-2007	Pharmacogenetics course, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden (attendance at research laboratory)
2006	4th European Summer School in Clinical Pharmacology & Therapeutics, Vrsac, Serbia (participant)
2006	Course "Inovations in Medical Education", Medical Faculty, Kragujevac, Serbia & School of Medicine, University of California, San Francisco, USA (participant)
2004-2005	Pharmacogenetics course, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden (attendance at research laboratory)
2005	7th Congress of the European Association for Clinical Pharmacology and Therapeutics, Poznan, Poland (participant)
2003	Seminar and workshop "Publishing in biomedicine", Vrsac, Serbia (participant)

Teaching

Undergraduate courses	<p>Clinical pharmacokinetics (course leader and lecturer)</p> <p>Pharmacology and toxicology (lecturer)</p> <p>Clinical pharmacology (lecturer)</p> <p>Physiology and pharmacology 1 with anatomy (lecturer)</p> <p>Physiology and pharmacology 2 with anatomy (lecturer)</p> <p>Physiology and pharmacology 3 (lecturer)</p> <p>Physiology and pharmacology 4 (lecturer)</p> <p>Introduction to pharmaceutical practice (lecturer)</p> <p>Physiology and pharmacology laboratory sessions (lecturer)</p> <p>Toxicology (lecturer)</p> <p>Pharmacoeconomics (lecturer)</p> <p>Pharmacoepidemiology (lecturer)</p> <p>Pharmacovigilance (lecturer)</p> <p>Pharmacotherapy in dentistry (lecturer)</p>
Postgraduate courses	<p>Pharmacogenetics and molecular neurobiology (course leader and lecturer)</p> <p>Neurosciences (lecturer)</p> <p>Clinical and experimental pharmacology (lecturer)</p> <p>Clinical and experimental surgery (lecturer)</p>
PhD candidates	<p>Radosavljevic Ivan, MD. Thesis title: The influence of genetic polymorphism of pancreas proteins and tumour necrosis factors on the course and outcome of acute pancreatitis.</p> <p>Dragana Dragas, MD. Thesis title: The influence of genetic polymorphism of drug metabolizing enzymes CYP3A4, CYP3A5, CYP2C8, CYP1A2, EPHX1 и UGT2B7 on efficacy and safety of carbamazepine therapy in children.</p>
CME courses	<p>The scientific importance and practical application of pharmacogenetics (course leader and lecturer)</p> <p>Health Economics - the doctors' role and the usefulness for the patient and the community (lecturer)</p>